TNF and inflammatory bowel disease: We did not include this trial in the meta-analysis on switching because it did not fulfil two important inclusion criteria; first, the trial did not recruit ‘IBD patients in remission while on originator anti-TNF’ because 39% of the patients were not in clinical remission when they were switched, at week 30 and, second, the 24-week follow-up period was too short to detect a difference in outcomes, unlike the two included RCTs which reported 1-year outcomes.